NEW YORK, March 9, 2026, 10:48 (EDT)
- Dianthus stock jumped roughly 22% early this day, after the company announced its CAPTIVATE CIDP trial reached an interim milestone earlier than planned.
- The biotech logged 20 confirmed responders before even hitting 40 patients through the initial study phase, and now says its cash runway extends into 2028.
Dianthus Therapeutics surged roughly 22% in morning New York trading Monday after the company reported its phase 3 CAPTIVATE trial of claseprubart in CIDP hit a key interim mark ahead of schedule, clearing the way for the study to continue. The biotech’s announcement focused on the rare autoimmune nerve disorder.
This update carries weight: CAPTIVATE is among Dianthus’ most significant 2026 catalysts. Just last November, the company bumped the interim analysis up to Q2 2026—earlier than previously planned—after enrollment moved quickly. The news also drops into a market where argenx’s Vyvgart is already approved for CIDP, while Sanofi has Phase 3 riliprubart trials underway.
Dianthus hit the threshold once 20 confirmed responders were logged, even before the initial 40 patients wrapped up the first stage of the study. Every participant in that phase got the drug. An independent safety board gave the go-ahead, according to the company, which also reported no drug-related serious infections, no related serious adverse events, and no discontinuations.
The company is sticking with its 300-mg under-the-skin, every-other-week dosing, while preparing to ask regulators to scrap the higher-dose arm from the second part of the trial. Planned enrollment for Part A drops to 256 from the original 480, which in turn lowers the Part B randomized group to 128 from 192. Timing for the main Part B readout: guidance still set to arrive by year-end 2026.
“The interim results bolster our confidence in claseprubart’s profile,” Chief Executive Marino Garcia said. James Sheffield, who leads CIDP development at Dianthus, pointed to “encouraging” consistency across multiple clinical measures. SEC
Dianthus released its trial update alongside its full-year numbers. For 2025, the company booked a net loss of $162.3 million, wider than the prior year’s $85.0 million. Cash, cash equivalents and investments totaled $514.4 million at year-end, enough to keep operations running through 2028.
Analysts struck an optimistic tone. William Blair’s Myles Minter described the numbers as a “best-case scenario” for now, Benzinga reported. Bill Maughan at Clear Street called the outcome “de-risking.” Truist hiked its price target to $110 from $63. Benzinga
Even so, this is just a preliminary snapshot. Dianthus noted the interim readout involved only a small patient group, warning the findings might not hold up for the rest of Part A or the randomized Part B trial. Regulatory signoff is also required before the higher-dose arm can be dropped.
Dianthus is lining up a Phase 3 trial for claseprubart in generalized myasthenia gravis, aiming to kick that off around mid-2026, with headline data expected in the back half of 2028. The company still targets the second half of 2026 for top-line readout from its Phase 2 trial in multifocal motor neuropathy (MMN). As for DNTH212, early data from healthy volunteers should arrive later this year.
